Articles On Prescient Therapeutics (ASX:PTX)

As the end of the day approaches, and with the benchmark struggling like a tired dog to keep its head above water, it’s time for us all to take a knee and rest awhile in front of a crackling fireplace and reminisce with a loved one about al...

SPI Futures imply the ASX 200 will start the day 1% lower Wall St struggled on Friday despite/because of robust jobs data US Q3 earnings to kick off with a big bank focus Local shares are poised to open lower on Monday with the ASX 200 No...

Aussie markets end Friday on a -0.80% disappointment US signals new cannabis laws, good news for Aussie producers Zelensky the hot tip to win a rare mid-war Nobel Peace Prize   The ASX has dribbled  it’s way towards Friday’s -0.80% close,...

CAR-T therapy is leading the race as the holy grail to cure cancer but like many medical therapies it is not without problems, which Prescient Therapeutics is working to overcome. Cancer is the second leading cause of death globally to hear...

Biotechnology investing provides investors chance for capital growth and to do social good ticking ESG boxes Ausbiotech receives increasing enquiries about gifting, bequesting or investing in medical companies for social good  Presicent sa...

Prescient has unveiled the latest technology in its cancer-fighting portfolio CellPryme-A at the 7th annual CAR-TCR Summit in Boston, the world’s pre-eminent forum in the CAR and TCR fields of cellular immunotherapy. Clinical stage oncolog...

Prescient Therapeutics (PTX) unveils a novel adjuvant for enhancing cellular immunotherapyCellPryme-A was designed to be administered to cancer patients as an intravenous infusion in combination with cellular immunotherapy, such as PTX’s CA...

At the world’s largest CAR-TCR meeting, Prescient Therapeutics (ASX: PTX) has debuted CellPryme-A, which is a novel adjuvant designed to be administered to cancer patients in combination with cellular immunotherapy such as CAR-T. CellPryme-...

Prescient will join with the US’s largest cancer centre with the goal of creating best-in-class, adaptable CAR-T cell therapies to treat hematological malignancies. Clinical stage oncology company Prescient Therapeutics (ASX:PTX) has signe...

Prescient Therapeutics (ASX: PTX) has entered a strategic collaboration with the largest cancer centre in US to create “best-in-class” adaptable CAR-T cell therapies to treat blood cancers. Under the collaboration, Prescient’s next generati...

Prescient Therapeutics (ASX: PTX) has entered a strategic collaboration with a renowned US cancer centre to create “best-in-class” adaptable CAR-T cell therapies to treat blood cancers. Under the collaboration, Prescient’s next generation C...

Prescient Therapeutics (PTX) partners with the largest cancer centre in the US to create best-in-class, adaptable CAR-T cell therapies to treat certain cancer typesThe company will collaborate with the University of Texas MD Anderson Cancer...

Prescient’s work is being considered a game-changer in advancing CAR-T therapies for cancer treatment and its leader believes its recent momentum is just the beginning. You can sense the excitement in the voice of Prescient Therapeutics (AS...

Got 90 seconds? Then listen to CEO & managing director, Steven Yatomi-Clarke tell us about their company news. Prescient Therapeutics (ASX:PTX) develop novel, personalised therapies for a range of cancers. The company has a broad pipeli...

Clinical stage oncology company Prescient Therapeutics to progress its deep pipeline of innovative cancer therapies with capital raise. The company is looking to raise $8 million in funds via a Share Purchase Plan at $0.175 per share to mai...

Prescient Therapeutics (ASX: PTX) has launched a capital raising targeting $8 million to maintain its momentum in developing its pipeline of innovative cancer and cell therapies and move towards first-in-human clinical studies. Prescient ha...

Clinical-stage oncology company developing personalised therapies Prescient Therapeutics (ASX:PTX) has announced a Share Purchase Plan (SPP) targeting to raise $8 million.

The Prescient Therapeutics Ltd (ASX: PTX) share price is plunging during late afternoon trade on Wednesday. This follows the company’s latest announcement regarding the launch of a share purchase plan (SPP). At the time of writing, share...

Prescient Therapeutics (PTX) is looking to raise $8 million via a share purchase plan (SPP) to progress its PTX-100 and PTX-200 cancer treatment therapies The company will also use the funds to progress its cell therapies to first-in-human...

Prescient has joined forces with Thermo Fisher Scientific for a research program aiming to advance development of its next-generation cellular therapies. Clinical stage oncology company Prescient Therapeutics (ASX:PTX) has signed an  agree...

Prescient Therapeutics (PTX) signs a deal with Thermo Fisher Scientific to accelerate the development of its OmniCar platform The work program will aim to develop the next generation OmniCAR cells that can be produced with greater efficien...

Australian biotech Prescient Therapeutics (ASX: PTX) has signed an agreement with US-based pharmaceutical services solutions company Thermo Fisher Scientific to accelerate development and commercialisation of a scalable version of its OmniC...

Prescient has entered a deal with the manufacturing arm of the world-renowned QIMR Berghofer Medical Research Institute in Brisbane to advance clinical trials of its OmniCAR cell lines.  Clinical stage oncology company Prescient Therapeuti...

Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has entered a services agreement with specialist cell therapy manufacturer Q-Gen Cell Therapeutics for the manufacture of its OmniCAR cell lines for upcoming clinical trials....

Prescient Therapeutics (PTX) strikes a manufacturing services agreement with Q-Gen Cell Therapeutics to produce its OmniCAR cell lines for its upcoming clinical trials The treatment will be studied against a range of cancers, but it is lik...

ShareCafeWebinar Recap – HPC, PTX, AR9 & MEK Catch up on the full webinar presentations from The Hydration Pharmaceutical Company (ASX HPC), Prescient Therapeutics (ASX: PTX), archTIS (ASX: AR9) & Meeka Metals (ASX: MEK) Webinar Re...

ShareCafePrescient Therapeutics (ASX: PTX) – Webinar Presentation Steven Yatomi-Clarke – CEO & MD – Prescient Therapeutics is focused on developing novel, personalised therapies for a range of cancers. Prescient Therapeutics (ASX: PTX)...

Oncology company Prescient Therapeutics (PTX) focused on advancing its targeted and cell therapies during the June quarter Promising trial data led the company to expand its PTX-100 therapy to treat T-cell lymphomas with recruitment expect...

Steven Yatomi-Clarke of Prescient Therapeutics speaks at the Switzer Small and Micro Cap Investor Strategy Day 2022.

The granting of an Orphan Drug Designation by the US FDA will grant PTX-100 market exclusivity and other commercial benefits in blood cancer PTCL. Clinical stage oncology company Prescient Therapeutics (ASX: PTX) announced that the US FDA h...

Prescient Therapeutics (PTX) receives orphan drug designation for its PTX-100 product for the treatment of peripheral T-cell lymphomas (PTCL) Orphan drug designation is given to drugs that are intended to treat rare diseases, and it gives...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

Prescient gets US patent approval Genetic Technologies expands EasyDNA into India and Europe Imricor submits cardiac ablation catheter for EU market Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has been granted a US p...

Prescient Therapeutics (PTX) is granted a key US patent for its OmniCAR universal immune receptor (UIR) platform The new patent protects Prescient’s two-part covalent binding system known as SpyTag and SpyCatcher, which forms a key compone...

Prescient is continuing to be a powerful force in the burgeoning personalised cancer treatment therapy sector, unveiling its latest platform to advance CAR-T therapy globally. Leading ASX oncology company developing personalised therapies...

Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has today unveiled the latest technology in its portfolio, a high-performance platform known as CellPryme-M which is designed to enhance cell therapies. Developed by Prescien...

Prescient Therapeutics (ASX:PTX) has announced the expansion of its Phase 1b clinical study of PTX-200 and cytarabine in patients with relapsed and refractory acute myeloid leukemia.

Prescient Therapeutics (PTX) expands its clinical study of patients with relapsed and refractory acute myeloid leukaemia (AML) The addition to the company’s Phase 1b clinical study of PTX-200 and cytarabine follows another complete patien...

XEC falls hard on Monday XOJ closes 1.2% lower Seafarms Group (ASX:SFG) recovers Friday losses   Australian markets fell and fell hard on Monday. The benchmark ASX200 is nudging two month lows, while the Greenback’s near 20-year high has...

Quarterlies: A data dump of intrigue and a smidgen of smoke and mirrors. But while the pain is akin to meeting your boyfriend’s parents, it always reveals a hell of a lot about the boy, inside the man. And so, Stockhead’s sublimely single b...

Prescient Thereapeutics gives hope with its personalised Car-T cell therapy Imugene working to activate the immune systems of cancer suffers to fight disease Rhythm Bioscience revolutionising the detection of bowel cancer According to th...

Prescient Therapeutics (PTX) opens patient enrolments for an expanded phase 1B trial of its PTX-100 therapy to treat T-cell lymphomas, a group of aggressive and rare blood cancers The company is looking to recruit eight to 12 patients suff...

Prescient Therapeutics (ASX: PTX) has begun recruiting for expanded clinical trial evaluating its drug PTX-100 in treating aggressive rare blood cancers where the company says there is a “significant unmet clinical need”. The company announ...

Investors have plenty of exciting updates to look forward as PTX advances clinical trials and its world-leading OmniCAR research platform. Clinical stage oncology company Prescient Therapeutics (ASX:PTX) updated the market with its half-yea...

Disclosure: The authors of this article and owners of Next Investors, S3 Consortium Pty Ltd, and associated entities, own 13,631,579 ALA shares. S3 Consortium Pty Ltd has been engaged by ALA to share our commentary on the progress of our in...

New data published in the science journal Nature has supported clinical stage oncology company Prescient Therapeutics’ (ASX: PTX) use of next generation cell therapy platform OmniCAR, which harnesses a patient’s own immune system to fight c...

Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has announced it has ended the December quarter with a cash balance of $14.77 million, placing it in a strong financial position to support its multiple cancer therapy progra...

With around $15m in the bank, Prescient is pressing ahead to move its novel OmniCAR therapy into the clinic as it looks to unlock shareholder value. Clinical stage oncology company Prescient Therapeutics (ASX:PTX) ended the quarter in a str...

It’s been another year of lockdown and supply challenges for all companies dealing with the COVID-19 variants as they pop up. But with challenges, comes opportunities to learn and grow. So as the end of the year approaches, we took the chan...